Clinical effect and brain network mechanism of transcutaneous auricular vagus nerve stimulation in the treatment of dysphagia after stroke

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500097423

Enrollment

Unknown

Registered

2025-02-19

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dysphagia after stroke

Interventions

Sham group:Both sides received sham stimulation, with a stimulation frequency of 25Hz, pulse width of 250µs, and intensity adjusted to a level where the patient could feel the stimulation without expe

Unilateral stimulation group:The left side received taVNS treatment, and the right side received sham stimulation. The stimulation frequency was 25Hz, pulse width was 250µs, and the intensity was adju

Bilateral stimulation group:Both sides received taVNS treatment, with a stimulation frequency of 25Hz, pulse width of 250µs, and intensity adjusted to a level where the patient could feel the stimulat

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed with ischemic stroke or hemorrhagic stroke according to the diagnostic criteria of the "China Cerebrovascular Disease Classification 2015" guidelines, and confirmed by CT or MRI; (2) First episode of stroke, with a duration of = 18 years; (4) Presence of penetration and/or aspiration confirmed by Fiberoptic Endoscopic Evaluation of Swallowing (FEES); (5) Water drinking test (Wakayama Test) score >= 3; (6) Informed consent signed by the patient or their family members.

Exclusion criteria

Exclusion criteria: (1) Swallowing dysfunction caused by other neurological diseases, such as Parkinson's disease, Alzheimer's disease, etc.; (2) Patients with active diseases of the auricle or external auditory canal; (3) Patients with implanted electroactive medical devices; (4) Patients with unstable vital signs or in the acute phase of the disease; (5) Patients with poor cognitive function who are unable to complete the related treatments and assessments.

Design outcomes

Primary

Measure	Time frame
swallowing function;	—

Secondary

Measure	Time frame
quality of life;	—

Countries

China

Contacts

Public ContactYinxu Wang; Jingjing Liu

Affiliated Hospital of North Sichuan Medical College

34089681@qq.com+86 134 3878 1951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026